CytoDyn Inc. (CYDY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CytoDyn Inc. (CYDY) with AI Score 47/100 (Weak). CytoDyn Inc. is a clinical-stage biotechnology company focused on developing treatments for various therapeutic indications, primarily centered around its drug candidate, leronlimab. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026CytoDyn Inc. (CYDY) Healthcare & Pipeline Overview
CytoDyn Inc. is a clinical-stage biotechnology firm specializing in the development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor. Its focus areas include COVID-19, oncology (metastatic triple-negative breast cancer and micro-satellite stable colorectal cancer), and collaborations like the one with Creatv Bio, positioning it within the competitive biotechnology sector.
Investment Thesis
CytoDyn Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is largely dependent on the successful clinical development and regulatory approval of leronlimab. Key value drivers include positive Phase 2 trial results for its oncology programs and potential partnerships for commercialization. The company's beta of 1.27 indicates higher volatility compared to the market. A significant risk factor is the company's reliance on a single drug candidate and the inherent uncertainty of clinical trials. Investors should closely monitor clinical trial outcomes and regulatory milestones to assess the company's progress. As of 2026-03-16, the company's market capitalization is $0.33 billion, reflecting investor sentiment and expectations regarding future success.
Based on FMP financials and quantitative analysis
Key Highlights
- CytoDyn Inc. is focused on the clinical development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor.
- Leronlimab is currently in Phase 2 clinical development for micro-satellite stable colorectal cancer and solid tumors, including metastatic triple-negative breast cancer.
- The company has a collaboration with Creatv Bio to advance its research and development efforts.
- CytoDyn's market capitalization is $0.33 billion as of 2026-03-16, reflecting investor sentiment.
- The company's beta of 1.27 indicates higher volatility compared to the market.
Strengths
- Novel therapeutic approach targeting the CCR5 receptor.
- Potential applications in multiple therapeutic areas.
- Collaboration with Creatv Bio.
Weaknesses
- Reliance on a single drug candidate.
- Limited financial resources.
- High risk of clinical trial failure.
Catalysts
- Upcoming: Phase 2 clinical trial results for micro-satellite stable colorectal cancer (timeline unknown).
- Upcoming: Phase 2 clinical trial results for metastatic triple-negative breast cancer (timeline unknown).
- Ongoing: Potential for new partnerships and collaborations.
- Ongoing: Regulatory updates regarding leronlimab's development.
Risks
- Potential: Clinical trial failures for leronlimab.
- Potential: Regulatory delays or rejection of leronlimab.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: Limited financial resources and dependence on external funding.
- Ongoing: Patent expiration and intellectual property challenges.
Growth Opportunities
- Expansion into New Oncology Indications: CytoDyn has the opportunity to expand the application of leronlimab into additional oncology indications beyond micro-satellite stable colorectal cancer and metastatic triple-negative breast cancer. This could involve targeting other solid tumors or hematological malignancies. The oncology drug market is projected to reach $250 billion by 2030, offering a substantial market opportunity for successful therapies. This expansion would require further clinical trials and regulatory approvals, with a potential timeline of 3-5 years.
- Partnerships and Collaborations: CytoDyn can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of leronlimab. These partnerships could provide access to additional funding, expertise, and distribution channels. The pharmaceutical industry is increasingly reliant on collaborations to drive innovation, with deal values reaching billions of dollars annually. A successful partnership could significantly enhance CytoDyn's market position and financial resources, with potential deals materializing within the next 1-2 years.
- Advancement of COVID-19 Program: Although the COVID-19 pandemic has subsided, CytoDyn could explore potential applications of leronlimab in treating long-term COVID-19 symptoms or other viral infections. The long-COVID market is still emerging, but some analysts estimate it could reach billions of dollars in the coming years. This would require additional clinical trials and regulatory approvals, with a potential timeline of 2-4 years.
- Geographic Expansion: CytoDyn can expand its clinical trials and commercialization efforts into new geographic regions, particularly in Asia and Europe, where there is a growing demand for innovative cancer therapies. The global oncology market is expanding rapidly, with emerging markets offering significant growth opportunities. This expansion would require regulatory approvals and partnerships with local distributors, with a potential timeline of 3-5 years.
- Leveraging Orphan Drug Designation: CytoDyn can seek orphan drug designation for leronlimab in specific rare cancer subtypes. Orphan drug designation provides several benefits, including market exclusivity and tax incentives, which can enhance the commercial viability of the drug. The orphan drug market is growing faster than the overall pharmaceutical market, driven by unmet medical needs and regulatory support. This designation could be pursued within the next 1-2 years, depending on the specific cancer subtype targeted.
Opportunities
- Expansion into new oncology indications.
- Strategic partnerships with larger pharmaceutical companies.
- Advancement of COVID-19 program.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Patent expiration.
Competitive Advantages
- Patent protection for leronlimab (limited information available).
- Clinical data supporting the efficacy of leronlimab (limited information available).
- Strategic collaborations with research institutions and other companies.
About CYDY
CytoDyn Inc., formerly RexRay Corporation, was founded in 2002 and is headquartered in Vancouver, Washington. It operates as a clinical-stage biotechnology company dedicated to developing innovative treatments for a range of therapeutic indications. The company's primary focus is on the clinical development of leronlimab, a humanized monoclonal antibody that targets the C-C chemokine receptor type 5 (CCR5). Leronlimab is being investigated for its potential in treating COVID-19, micro-satellite stable colorectal cancer, and solid tumors, including metastatic triple-negative breast cancer. CytoDyn's approach involves strategic collaborations, such as its partnership with Creatv Bio, to advance its research and development efforts. The company is currently in Phase 2 clinical development for several of its oncology programs. CytoDyn aims to address unmet medical needs through its targeted therapies, navigating the complex regulatory landscape to bring its products to market.
What They Do
- Develops leronlimab, a humanized monoclonal antibody.
- Targets the CCR5 receptor for therapeutic intervention.
- Conducts clinical trials for COVID-19 treatment.
- Investigates leronlimab for micro-satellite stable colorectal cancer.
- Explores leronlimab's potential in treating metastatic triple-negative breast cancer.
- Collaborates with Creatv Bio for research and development.
Business Model
- Focuses on developing and commercializing leronlimab.
- Generates revenue through potential future sales of leronlimab.
- Relies on partnerships and collaborations for funding and expertise.
Industry Context
CytoDyn Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for oncology drugs is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like CytoDyn are striving to develop novel therapies that address unmet medical needs. The success of biotechnology companies depends on their ability to navigate the regulatory landscape, secure funding, and demonstrate clinical efficacy. The biotechnology industry is subject to rapid technological advancements and evolving scientific understanding, requiring companies to remain innovative and adaptable.
Key Customers
- Patients with COVID-19 (potential future market).
- Patients with micro-satellite stable colorectal cancer (clinical trial participants).
- Patients with metastatic triple-negative breast cancer (clinical trial participants).
Financials
Chart & Info
CytoDyn Inc. (CYDY) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Wednesday
· Jan 29, 2020
-
Stocks That Hit 52-Week Highs On Friday
· Dec 27, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CYDY.
Price Targets
Wall Street price target analysis for CYDY.
MoonshotScore
What does this score mean?
The MoonshotScore rates CYDY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
CYDY OTC Market Information
The OTCQB Venture Market is the middle tier of the over-the-counter (OTC) market, designed for developing companies. Unlike the NYSE or NASDAQ, OTCQB companies have more lenient listing requirements, making it accessible for smaller or early-stage businesses. To qualify for OTCQB, companies must meet minimum financial standards, follow SEC reporting guidelines (or the Pink Basic Disclosure Guidelines if they are not SEC reporting), and undergo an annual verification process. This tier offers more visibility and credibility compared to the lower OTC Pink market but less than the major exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight compared to major exchanges.
- Lower liquidity and higher price volatility.
- Potential for less stringent financial reporting requirements.
- Increased risk of fraud or manipulation.
- Dependence on a single drug candidate.
- Verify the company's financial disclosures on the OTC Markets website.
- Review the company's SEC filings (if applicable).
- Assess the company's management team and their track record.
- Evaluate the company's clinical trial data and regulatory prospects.
- Analyze the company's competitive landscape and market potential.
- Monitor the company's news releases and investor relations materials.
- Understand the risks associated with investing in OTCQB-listed companies.
- OTCQB listing indicates a certain level of financial and reporting compliance.
- Collaboration with Creatv Bio suggests external validation of the company's technology.
- Clinical trials underway for leronlimab indicate ongoing research and development efforts.
CytoDyn Inc. Stock: Key Questions Answered
What does CytoDyn Inc. do?
CytoDyn Inc. is a clinical-stage biotechnology company focused on developing leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor. The company is currently conducting clinical trials to evaluate leronlimab's potential in treating various indications, including micro-satellite stable colorectal cancer, metastatic triple-negative breast cancer, and potentially COVID-19. CytoDyn's business model revolves around advancing leronlimab through clinical development, securing regulatory approvals, and ultimately commercializing the drug, either independently or through partnerships.
What do analysts say about CYDY stock?
As of 2026-03-16, formal analyst coverage of CYDY stock is limited due to its OTCQB listing and clinical-stage nature. However, investor sentiment and valuation are primarily driven by the progress of leronlimab's clinical trials and regulatory prospects. Key metrics to consider include the company's market capitalization ($0.33 billion), cash burn rate, and potential revenue from future sales of leronlimab. Investors should closely monitor clinical trial outcomes and regulatory milestones to assess the company's growth potential and valuation.
What are the main risks for CYDY?
The primary risks for CytoDyn Inc. include the inherent uncertainty of clinical trials, the potential for regulatory delays or rejection, and competition from established pharmaceutical companies. The company's reliance on a single drug candidate, leronlimab, also poses a significant risk. Furthermore, CytoDyn's limited financial resources and dependence on external funding could impact its ability to advance its clinical programs. Investors should carefully consider these risks before investing in CYDY stock.
What are the key factors to evaluate for CYDY?
CytoDyn Inc. (CYDY) currently holds an AI score of 47/100, indicating low score. Key strength: Novel therapeutic approach targeting the CCR5 receptor.. Primary risk to monitor: Potential: Clinical trial failures for leronlimab.. This is not financial advice.
How frequently does CYDY data refresh on this page?
CYDY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CYDY's recent stock price performance?
Recent price movement in CytoDyn Inc. (CYDY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel therapeutic approach targeting the CCR5 receptor.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CYDY overvalued or undervalued right now?
Determining whether CytoDyn Inc. (CYDY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CYDY?
Before investing in CytoDyn Inc. (CYDY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on specific financial metrics and analyst coverage.
- OTC listing increases investment risk.